Electronic Batch Record (eBR): What It Is and Why It Matters

An eBR is the complete, structured, signed record of a single batch's manufacture — from material issue through every recipe step, every in-process check, every signature, every deviation, every yield reconciliation, to release or rejection. The defining property is that it is *the* record, not a representation of one: an inspector reviewing the eBR is reviewing the original. In a real eBR every step is signed at the moment it happens by an authenticated user; the audit trail captures before-and-after values with mandatory reason-for-change; deviations are linked structured records, not free-text notes; the eBR cannot be edited after release except through formal change control. A scanned PDF of a paper traveller is not an eBR — it's a digital photocopy.

Four regulatory threads converge on the eBR. (1) 21 CFR 211.188 (drug cGMP) requires complete batch production and control records with every significant step documented, dated and signed. (2) 21 CFR 212 (PET drugs) and 21 CFR 600s (biologics) add domain-specific records. (3) 21 CFR 820.184 (device QSR) defines the equivalent eDHR — Device History Record — for finished medical devices, requiring the dates, quantities, acceptance records, identification labels and UDI for each device. (4) EU GMP Chapter 4 + Annex 11 set the EU equivalent, with explicit electronic-record provisions in Annex 11. 21 CFR Part 11 sits on top of all of this — any record above that is electronic must meet the Part 11 controls. Add ICH Q7, Q9, Q10 for the principles, and the supplement (21 CFR 111.260) and food (21 CFR 117) equivalents, and the eBR / eDHR is effectively a universal requirement across regulated manufacturing.

Six properties separate a real eBR from compliance theatre. (1) Step-by-step e-signature with structured meaning (Author / Reviewer / Approver / QA Release), not free-text checkboxes. (2) Out-of-sequence enforcement: the operator can't sign step 7 before step 6. (3) Live audit trail with before / after values and mandatory reason-for-change on every regulated edit. (4) Structured deviation capture at the point of failure, linked to the eBR step that triggered it. (5) Material lot identity captured at consumption — every input lot traceable forward to this eBR and every output lot traceable back. (6) Review-by-exception: the reviewer sees only the steps that deviated or need attention, not 200 pages of healthy sign-offs. Strip any of these out and the eBR is harder to defend than the paper traveller it replaced.

Three line items dominate. (1) Batch-release cycle time: paper batch records typically take 3–10 days to assemble, review and release; a live signed eBR is reviewable in hours because the record is born complete. (2) Right-first-time release: paper batch records routinely come back from QA with sign-off gaps, missing initials, ambiguous corrections — each requiring a deviation and rework cycle. A live eBR rejects these at point of capture, so QA review is exceptional rather than routine. (3) Inspection prep: an inspector asks for batch X; with paper or hybrid, that's a binder hunt and re-printing; with a live eBR, that's a one-click export of the live record with full audit trail. Companies on paper or hybrid spend weeks preparing for an inspection; eBR-native plants spend an afternoon.

For medical devices, the equivalent of an eBR is the eDHR (electronic Device History Record), defined by 21 CFR 820.184 and harmonised under the FDA QMSR with ISO 13485. The structure differs slightly — the eDHR carries acceptance records, identification labels, UDI and shipping records as first-class fields; the eBR carries yield, in-process specs and component reconciliation. The discipline is identical: live signed steps, structured deviations, linked lot / serial identity, review-by-exception, no editing after release except through change control. The same platform should run both — running pharma eBR on one product and device eDHR on another is a stack-cost trap a modern unified platform avoids.

Five mistakes cost the most. (1) Treating eBR as a document module rather than as the way production runs — if operators still fill paper and someone re-types it, you bought a digital filing cabinet, not an eBR. (2) Skipping out-of-sequence enforcement to 'avoid annoying operators' — the enforcement is the value. (3) Not capturing reason-for-change on edits — the audit trail becomes uninspectable. (4) Free-text deviations instead of structured ones — the link to CAPA breaks. (5) Not linking the eBR to live ERP inventory write-back — finance and operations diverge. The unifying mistake is buying eBR as a compliance bolt-on rather than as the operating system of the floor. Buy it that way and it pays back; buy it as a documentation tool and it doesn't.